Global transmission network and driving mechanisms: An epidemiological and genomic study of bla OXA -mcr co-carrying strains

Imagine a world where the most powerful antibiotics we have, the ones doctors save for when everything else fails, stop working. For decades, two specific classes of drugs have served as this final line of defense: carbapenems, used to treat severe infections, and colistin, a drug once set aside because of its side effects but now essential for the toughest cases. Bacteria are evolving to defeat these drugs, but a new and terrifying development has emerged. Scientists have discovered that some bacteria are now carrying two different resistance genes at the same time: one that blocks carbapenems and another that blocks colistin. When a single bacterium holds both, it becomes a "super-bug" that leaves doctors with no effective treatment options. This is not just a theoretical risk; it is a growing reality that threatens to undo decades of medical progress.

A team of researchers set out to understand how these dual-resistant bacteria are spreading across the globe. They did not look at a single hospital or a single country; instead, they looked at the entire world. By analyzing thousands of bacterial genetic codes stored in a massive public database, they tracked down every instance where a bacterium carried both the carbapenem-resistance gene and the colistin-resistance gene. Their goal was to map out where these bacteria are found, how they move between people, animals, and the environment, and what genetic tools they use to travel so effectively. The result is a detailed picture of a silent, global transmission network that crosses borders and species lines with alarming ease.

The researchers examined genetic data from 3,665 bacterial samples collected between 1953 and 2024. From this vast pool, they identified 284 specific strains that carried both resistance genes. These bacteria were found in 30 different countries, but the distribution was not even. Germany had the highest number of reported cases, accounting for nearly half of all the strains found. Spain, the United Kingdom, Singapore, and China also appeared frequently in the data. The bacteria themselves were mostly a group known as Enterobacteriaceae, which includes common species like E. coli and Klebsiella pneumoniae. While the first strain found was a different type of bacterium called Acinetobacter baumannii, the vast majority of the dual-resistant bacteria discovered in recent years belong to the Enterobacteriaceae family.

The most common combination of resistance genes found in these bacteria was a specific pair: a gene called blaOXA-48 and a gene called mcr-10. This specific pairing appeared in more than three-quarters of the cases the researchers studied. The study also revealed that these bacteria are not just found in sick people in hospitals. Since 2016, scientists have detected them in pets like cats and dogs, in livestock such as pigs, and even in environmental samples like water and soil. This shift suggests that the bacteria have expanded their reach from human patients to a much wider ecological network, moving freely between people, their animals, and the world around them.

To understand how these bacteria move, the researchers built a family tree based on the genetic code of the 284 strains. This tree showed that the bacteria are not just appearing randomly in different places; they are traveling. The analysis uncovered specific instances where bacteria from different countries were so genetically similar that they must have come from the same source. For example, one pair of bacteria, one found in Romania in 2016 and another in the United Kingdom in 2020, differed by only a single tiny change in their genetic code. This suggests that a single strain of bacteria traveled from poultry in Romania to an environmental sample in the UK over four years, remaining almost unchanged. Other connections linked bacteria from China to the UK, and from Thailand to France, proving that these dual-resistant strains are crossing continents.

The study also looked at the machinery inside the bacteria that allows these resistance genes to spread. The researchers found that the genes are often carried on small, circular pieces of DNA called plasmids, which act like delivery vehicles. These plasmids can jump from one bacterium to another, even between different species. The most common delivery vehicles found were two specific types of plasmids: one that carries the carbapenem-resistance gene and another that carries the colistin-resistance gene. These two plasmids often work together, moving the resistance genes through bacterial populations efficiently. Interestingly, the researchers noticed that the genetic structures surrounding these resistance genes have become simpler over time. This simplification likely makes it easier for the bacteria to carry the genes without suffering a penalty to their own survival, allowing them to spread more effectively.

The timeline of the discovery shows a clear pattern. The number of reported cases rose steadily from 2013, reached a peak in 2019, and then declined sharply. However, the decline does not necessarily mean the problem has gone away. The researchers suggest that the drop might be due to changes in how countries track these bacteria or the success of local interventions in specific places. For instance, the data from the United Kingdom showed a burst of cases between 2014 and 2016 followed by a drop, while Germany showed a steady, continuous presence of these bacteria over many years. This difference suggests that while the bacteria are present globally, the ability to detect them depends heavily on how well a country monitors its hospitals, farms, and environment.

The study highlights a critical gap in our knowledge. While Germany reported the most cases, the researchers believe this is likely because Germany has a very active system for finding these bacteria, including testing wastewater. In many other parts of the world, particularly in low- and middle-income countries, the true number of cases is probably much higher than what is recorded because these regions lack the same level of surveillance. The bacteria are likely spreading in places where we simply do not have the tools to see them. The fact that these bacteria have moved from human patients to pets and the environment means that traditional hospital measures are not enough to stop them.

Ultimately, the research paints a picture of a complex, interconnected threat. These dual-resistant bacteria have formed a global network that transcends national borders, species barriers, and the divide between humans and nature. They are driven by a combination of highly mobile genetic vehicles and stable bacterial clones that can survive in diverse environments. The findings suggest that to stop the spread, we need a coordinated approach that looks beyond the hospital walls. We must monitor these bacteria in our communities, our farms, and our environment, understanding that the health of people, animals, and the planet are inextricably linked. Without a global effort to track and intervene, these silent travelers will continue to erode our ability to treat the most dangerous infections.